Ubrelvy, a medication used to treat acute migraine, contains several inactive ingredients. These include microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate [1]. The capsule shell is made of hypromellose, titanium dioxide, and red iron oxide [1]. These components are common excipients used in pharmaceutical formulations to aid in drug delivery and stability [2].
What are the active ingredients in Ubrelvy?
The active ingredient in Ubrelvy is ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. Ubrogepant works by blocking the action of CGRP, a molecule involved in migraine pain [3].
How does Ubrelvy work to treat migraines?
Ubrelvy targets the CGRP pathway, which is believed to play a significant role in the pathophysiology of migraine [3]. By inhibiting the binding of CGRP to its receptor, ubrogepant helps to reduce the inflammation and vasodilation associated with migraine attacks [3].
Are there any known side effects of Ubrelvy?
Common side effects associated with Ubrelvy include nausea, diarrhea, and fatigue [1]. Less common but more serious side effects can include liver problems [1]. Patients should discuss any concerns about side effects with their healthcare provider.
What is the typical dosage for Ubrelvy?
Ubrelvy is typically prescribed at a dose of 50 mg or 100 mg taken orally as needed for migraine with or without aura [1]. It is not intended for the prevention of migraines [1].
When did Ubrelvy receive FDA approval?
Ubrelvy was approved by the U.S. Food and Drug Administration (FDA) in December 2019 [4].
What is the patent status for Ubrelvy?
The primary patent covering Ubrelvy is U.S. Patent No. 9,782,402 [5]. This patent is set to expire in 2036 [5]. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceutical products, which can inform the potential for generic competition [6].
How does Ubrelvy compare to other migraine treatments?
Ubrelvy belongs to a class of drugs known as CGRP antagonists, which differ from older migraine treatments like triptans or ergots. Triptans work by constricting blood vessels, while Ubrelvy targets the CGRP pathway [3]. Other CGRP antagonists include rimegepant (Nurtec ODT) and atogepant (Qulipta), which are also used for migraine treatment [3].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [1].
Can Ubrelvy be used for migraine prevention?
No, Ubrelvy is indicated for the acute treatment of migraine and is not intended for migraine prevention [1].
Sources:
[1] https://www.ubrelvy.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814122/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6793363/
[4] https://www.prnewswire.com/news-releases/fda-approves-ubrelvy-ubrogepant-abbvies-first-small-molecule-calcitonin-gene-related-peptide-receptor-antagonist-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults-300975493.html
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/